Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

Biomedicines, Free Full-Text

eBioMedicine, Vol 93, July 2023

Ida H Hiemstra's research works Genmab, Copenhagen and other places

CD38 in the age of COVID-19: a medical perspective

IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners - eBioMedicine

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. - Abstract - Europe PMC

IJMS, Free Full-Text

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies